<DOC>
	<DOCNO>NCT00411814</DOCNO>
	<brief_summary>This two part study . Part I design test single dos GSK678586A healthy volunteer . Part II design test repeat dos ( two dos ) GSK679586A patient mild asthma . Both part design investigate safety , tolerability way body absorbs GSK679586A give intravenous infusion ( vein arm ) .</brief_summary>
	<brief_title>A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : Men age 18 65 year inclusive , woman age 18 50 year inclusive . Female subject must nonchildbearing potential , Male subject must agree abstain sexual intercourse use adequate contraception sexual intercourse pregnant lactating female , addition female partner use another form contraception . This criterion must follow time first dose study medication 84 day last dose study medication . Body weight ≥ 50 kg BMI within range 19 29.9 kg/m2 . Nonsmoker verify urinary cotinine level 300 ng/mL screen exsmokers give smoke &gt; 12 month history &lt; 10 pack year [ Pack yr = ( No cigarettes/day x No year smoke ) /20 ] Available complete study measurement . Able read , comprehend , write English sufficient level complete study related material . Capable give write informed consent , include compliance requirement restriction list consent form Additional Inclusion Criteria Subjects Part I • Healthy determine responsible physician , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . Additional Inclusion Criteria Subjects Part II History asthma least 6 month prior screen visit currently require treatment intermittent treatment inhale shortacting beta2agonist . Subject must receive low dose inhale corticosteroid within three month prior Day 0 . Prebronchodilator FEV1 &gt; 70 % &lt; 90 % predict screening ≥12 % reversibility shortacting beta2agonist If subject prebronchodilator FEV1 ≥90 % screen history asthma subject meet FEV1 criterion demonstrate ≥12 % reversibility shortacting beta2agonist administration , subject may consider eligible Bronchial Provocation Test asthma positive ( consultation Medical Monitor Principal Investigator ) . The bronchial provocation consider positive standard criterion positive response give challenge agent met . Skin prick test positive allergen appropriate nasal challenge Exclusion criterion : As result medical interview , physical examination screen investigation , responsible physician deem subject unsuitable study . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation . Previous exposure humanise antibody therapy reason . A strong family history Th1 cytokinerelated inflammatory disorder , include limited , Type I diabetes mellitus , multiple sclerosis , Crohn 's disease , rheumatoid arthritis , sarcoidosis . Known history active latent tuberculosis , recent ( within 6 month study enrolment ) exposure person active tuberculosis . Previous medical history letter subject 's physician ( GP ) exclude . A history chronic urogenital infection chronic infection . Subjects receive type vaccination last two month . The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication Where participation study would result donation blood excess 500 mL within 56 day period Exposure four new chemical entity within 12 month prior first dose day Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John'sWort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety . History alcohol/drug abuse dependence within 12 month study : Abuse alcohol define average weekly intake great 21 unit average daily intake great 3 unit ( male ) define average weekly intake great 14 unit average daily intake great 2 unit ( female ) . 1 unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test human immunodeficiency virus ( HIV ) antibody . The subject positive prestudy urine drug/ urine alcohol screen . A minimum list drug screen include Amphetamines , Barbiturates , Cocaine , Opiates , Cannabinoids Benzodiazepines . ECG outside range define protocol Those , opinion Investigator , risk noncompliance study procedure . The subject history confirm active parasitic infection . The subject unable refrain travel country high prevalence infectious ( especially parasitic ) disease first dose administer expect washout period complete ( plasma level LLQ ) last followup visit , ever later</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>melbourne ,</keyword>
	<keyword>healthy</keyword>
	<keyword>antibody ,</keyword>
	<keyword>male ,</keyword>
	<keyword>Safety pharmacokinetic study ,</keyword>
	<keyword>mild asthmatic patient ,</keyword>
	<keyword>australia</keyword>
	<keyword>monoclonal</keyword>
	<keyword>female ,</keyword>
	<keyword>volunteer ,</keyword>
</DOC>